Neuphoria Therapeutics Inc (NEUP)

Neuphoria Therapeutics Inc. is a biotechnology company focused on developing therapies for central nervous system disorders, with a listing on NASDAQ through an ADR structure. The company is in the clinical stage and is working on novel allosteric ion channel modulators. Its lead candidate, BNC210, is a selective negative allosteric modulator of the a7 receptor being studied for social anxiety disorder and is also in phase 2b development for post-traumatic stress disorder. Neuphoria is also advancing BNC101, a monoclonal antibody that has completed a phase 1 trial and targets cancer stem cells, as well as BNC105 for cancer. Additional programs include NextGen, which is in preclinical development for multiple central nervous system indications, and a Kv3.1/3.2 agonist being evaluated for potential cognitive deficits and negative symptoms or social withdrawal in schizophrenia and autism spectrum disorders. The company also has a collaboration with Merck & Co., Inc. on a7 receptor positive allosteric modulators for cognitive dysfunction associated with Alzheimer’s disease and other central nervous system conditions. Formerly known as Bionomics Limited, the company adopted the Neuphoria Therapeutics Inc. name in December 2024 and is based in Burlington, Massachusetts.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.